- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Myriad holds monopoly for BRCA1/BRCA2 testing
Myriad Genetics is the only place to go for BRCA1/BRCA2 mutation testing. The Salt Lake City biopharmaceutical company has a monopoly on the test. Its scientists discovered the BRCA1 and BRCA2 genes in 1996 and patented their use for assessing the risk of genetically related cancer.
Myriad Genetics is the only place to go for BRCA1/BRCA2 mutation testing. The Salt Lake City biopharmaceutical company has a monopoly on the test. Its scientists discovered the BRCA1 and BRCA2 genes in 1996 and patented their use for assessing the risk of genetically related cancer.
According to a Myriad spokesperson, 50,000 BRCA1 and BRCA2 genetic tests were performed in 2006, compared with 35,000 in 2005. The firm expects demand to rise again about 43% this year. The automated gene sequencing technology covers 85% to 90% of genetically related breast cancer. Results from about 15 of every 100 tests are positive.
Testing charges vary. It costs $3200 to test the first person in a family, according to Robert Resta, a genetic counselor with Swedish Medical Center in Seattle. Testing first-degree relatives-parents, siblings, and children-costs an additional $400 per person. For Ashkenazi Jews, the test costs about $500 because their susceptibility is based on fewer mutations than the general population, thereby requiring a simpler test, Resta said.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.
